Boehringer Ingelheim and BioNTech Partner on Novel SCLC Combination Therapy Trial
Event summary
- Boehringer Ingelheim and BioNTech will collaborate on a Phase Ib/II trial combining obrixtamig (DLL3-targeting T-cell engager) with pumitamig (PD-L1/VEGF-A bispecific antibody) for extensive-stage small cell lung cancer (ES-SCLC).
- The trial aims to assess safety, tolerability, and early clinical activity, with dosing expected to begin in the second half of 2026.
- Obrixtamig has shown a 68% confirmed objective response rate in prior studies, while pumitamig demonstrated a 76.3% response rate in combination with chemotherapy.
- Both companies retain full rights to their respective assets, and the agreement is mutually non-exclusive.
The big picture
This collaboration targets two critical barriers in SCLC: immune evasion and an immunosuppressive, pro-angiogenic microenvironment. The trial builds on prior successes of both obrixtamig and pumitamig, which have shown promising results in separate studies. The partnership underscores the growing trend of combining complementary immunotherapeutic mechanisms to enhance antitumor immunity in aggressive cancers.
What we're watching
- Clinical Efficacy
- Whether the combination of obrixtamig and pumitamig can deliver more sustained tumor control in SCLC, a cancer with high unmet medical need.
- Regulatory Pathway
- The pace at which the trial progresses and whether it supports accelerated approval pathways given the aggressive nature of SCLC.
- Competitive Landscape
- How this collaboration positions Boehringer Ingelheim and BioNTech against other immuno-oncology combinations in development for SCLC.
Related topics